Skip to main content
SpringerLink
Log in

Intravenous iron treatment: a comparison of available drugs

  • Chapter
Renal Anemia

  • 113 Accesses

Abstract

Iron supplementation is an important component of anemia treatment for patients on hemodialysis. Iron deficiency develops in these patients for three primary reasons. First, chronic blood loss related to dialysis apparatus blood retention, accidental and surgical blood loss and blood testing [1–3]. Second, the use of phosphate binders interferes with dietary iron absorption [3]. Third, epoetin alfa treatment stimulates rapid production of red blood cells, creating a deficiency of immediately available circulating iron [4–5]. The net result is that iron deficiency is common in hemodialysis patients, and is an important factor that may hinder the achievement of target hemoglobin levels [6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bone JM. Blood loss and iron requirements in patients on haemodialysis. Scott Med J. 1972;17(8):264–5.

    PubMed  CAS  Google Scholar 

  2. Akmal M, Sawelson S, Karubian F, Gadallah M. The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol. 1994;42(3):198–202.

    PubMed  CAS  Google Scholar 

  3. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis. 1997;29(3):319–33.

    Article  PubMed  CAS  Google Scholar 

  4. Brugnara C, Colella GM, Cremins J, Langley RC Jr, Schneider TJ, Rutherford CJ, Goldberg MA. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med. 1994;123(5):660–7.

    PubMed  CAS  Google Scholar 

  5. Rutherford CJ, Schneider TJ, Dempsey H, Kirn DH, Brugnara C, Goldberg MA. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response. Am J Med. 1994;96(2):139–45.

    Article  PubMed  CAS  Google Scholar 

  6. Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis. 2001;38(1):109–17.

    Article  PubMed  CAS  Google Scholar 

  7. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26(1):41–6.

    Article  PubMed  CAS  Google Scholar 

  8. Sepandj F, Jindal K, West M, Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplantation. 1996;11(2):319–22.

    Article  CAS  Google Scholar 

  9. Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplantation. 1995;10(11):2070–6.

    CAS  Google Scholar 

  10. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol. 1997;48(1):34–40.

    PubMed  CAS  Google Scholar 

  11. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron. 1998; 79(3):299–305.

    Article  PubMed  CAS  Google Scholar 

  12. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50(5):1694–9.

    Article  PubMed  CAS  Google Scholar 

  13. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int. 1999;69:S61–6.

    Article  CAS  Google Scholar 

  14. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis. 1997;30(4 supplement 3):S192–240.

    Google Scholar 

  15. Cameron JS. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplantation. 1999;14 (supplement 2):61–5.

    Article  Google Scholar 

  16. Cowley JM, Janney DE, Gerkin RC, Buseck PR. The structure of ferritin cores determined by electron nanodiffraction. J Struct Biol. 2000;131(3):210–6.

    Article  PubMed  CAS  Google Scholar 

  17. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung. 1992;42(12):1439–52.

    PubMed  CAS  Google Scholar 

  18. Bailey G, Strub RL, Klein RC, Salvaggio J. Dextran-induced anaphylaxis. JAMA. 1967;200(10):889–91.

    Article  PubMed  CAS  Google Scholar 

  19. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996;28 (4):529–34.

    Article  PubMed  CAS  Google Scholar 

  20. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980;243(17):1726–31.

    Article  PubMed  CAS  Google Scholar 

  21. Faich G, Strobos G. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999;33(3):464–70.

    Article  PubMed  CAS  Google Scholar 

  22. Novey HS, Pahl M, Haydik I, Vaziri ND. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy. 1994;72(3):224–8.

    PubMed  CAS  Google Scholar 

  23. Fishbane S, Lynn RL The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol. 1995;44(4):238–40.

    PubMed  CAS  Google Scholar 

  24. Bailie GR, Johnson CA, Mason NA. Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis. 2000;35(1):1–12.

    Article  PubMed  CAS  Google Scholar 

  25. Navarro JF, Teruel JL, Liano F, Mareen R, Ortuno J. Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. Am J Nephrol. 1996;16:268–72.

    Article  PubMed  CAS  Google Scholar 

  26. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplantation. 1996;11(6):1079–83.

    Article  CAS  Google Scholar 

  27. Braun J, Lindner K, Schreiber M, Heidler RA, Hörl WH. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplantation. 1997;12:1173–81.

    Article  CAS  Google Scholar 

  28. Cortes MJC, Perales MCS, Utiel FJB, Serrano P, Del Barrio PP, Liebana A, Hinojosa JB, Marcos SG, Banasco VP. Effect of intravenous Na-Fe-gluconate in hemodialysis patients treating with rHuEPO. Nefrologia. 1997;17:424–9.

    Google Scholar 

  29. Pascual J, Teruel JL, Liano F, Sureda A, Ortuno J. Intravenous Fe-gluconate-Na for iron-deficient patients on hemodialysis. Nephron. 1992;60:121 (letter).

    Google Scholar 

  30. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients. N Am Clin Trial. Am J Kidney Dis. 1999;33:471–82.

    Article  CAS  Google Scholar 

  31. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, Th de Jong GM. ‘Oversaturation’ of transferrin after intravenous ferric gluconate (Ferrlicet(R)) in haemodialysis patients. Nephrol Dial Transplantation. 1996;11:820–4.

    Article  CAS  Google Scholar 

  32. Seligman PA, Schleicher RB. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem. 1999;45(6 Pt 1):898–901.

    PubMed  CAS  Google Scholar 

  33. Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am] Kidney Dis. 2001;37(2):300–7.

    Article  CAS  Google Scholar 

  34. Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis. 2000;36(1):88–97.

    Article  PubMed  Google Scholar 

  35. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron. 1996;72(3):41 3–7.

    Article  Google Scholar 

  36. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplantation. 2001;16(5):967–74.

    Article  CAS  Google Scholar 

  37. Hoigne R, Breymann C, Kunzi UP, Brunner F. Parenteral iron therapy: problems and possible solutions. Schweiz Med Wochenschr. 1998;128(14):528–35.

    PubMed  CAS  Google Scholar 

  38. Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J. 1998;45(4):431–9.

    Article  PubMed  CAS  Google Scholar 

  39. Suzuki A, Ohoike H, Matsuoka Y, Irimajiri S. Iatrogenic osteomalacia caused by intravenous administration of saccharated ferric oxide. Am J Hematol. 1993;43 (1):75–6.

    Article  PubMed  CAS  Google Scholar 

  40. Okada M, Imamura K, Iida M, Fuchigami T, Omae T. Hypophosphatemia induced by intravenous administration of Saccharated iron oxide. Klin Wochenschr. 1983;61(2):99–102.

    Article  PubMed  CAS  Google Scholar 

  41. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplantation. 2000;15 (11):1827–34.

    Article  CAS  Google Scholar 

  42. Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int. 1999;69:S71–8.

    Article  CAS  Google Scholar 

  43. Sunder-Plassmann G, Horl WH. Comparative look at intravenous iron agents: Pharmacology, efficacy, sand safety of iron dextran, iron saccharate and ferric gluconate. Semin Dial. 1999;12(4):243–8.

    Article  Google Scholar 

Download references

Authors
  1. Steven Fishbane
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Inpatient Dialysis Services, SUNY Downstate Medical Center, Brooklyn, New York, USA

    Onyekachi Ifudu (Associate Professor of Medicine, Director) (Associate Professor of Medicine, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Fishbane, S. (2002). Intravenous iron treatment: a comparison of available drugs. In: Ifudu, O. (eds) Renal Anemia. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9998-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-94-015-9998-6_14

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-6045-7

  • Online ISBN: 978-94-015-9998-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation